EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 739 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR The Nobel Prize winner helping us treat children’s cancers November 8, 2022 Nursing Professor Who Used Her Breast Cancer Diagnosis as a Teaching... December 7, 2020 Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers April 25, 2019 ¿Qué son los biosimilares para el tratamiento del cáncer? November 30, 2021 Load more HOT NEWS FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... Significant Activity, Clinically Meaningful Functional and Symptomatic Improvements Observed in Patients... EMA Recommends Granting a Conditional Marketing Authorisation for Alpelisib Elucidating a Risk of Developing Second Primary Malignancy During and After...
